PharmaTelevision - Cellzome: Tim Edwards explains Cellzome's technology and talks about their collaboration strategy

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cellzome: Tim Edwards explains Cellzome's technology and talks about their collaboration strategy

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tim Edwards, CEO of Cellzome

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Cellzome's technology

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Oxford. On this show I have Tim Edwards, who is the President and CEO of Cellzome a company that's in Heidelberg, but also based in Cambridge, welcome to the show.

Tim Edwards:

Thank you Fintan.

Fintan Walton:

Tim, Cellzome as I said is an interesting company, it's a discovery based company originally it's been doing lots of deals, could you tell us first of all about what is it about Cellzome that it makes so attractive to other companies to do deals with you?

Tim Edwards:

Right, well we are leaders in the field of chemical proteomics in fact we would probably consider ourselves to be world leaders in that field and that technology platform is very useful for opening up and understanding a new areas of biology and as we see the discovery of new medicines getting ever more complicated so pharma partners and large biotech's are approaching us to try and use our technology.

Fintan Walton:

So could you be little more specific Tim about the exact technology that Cellzome has?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Tim Edwards

President

Tim Edwards is currently President and Chief Executive Officer of Cellzome Inc , a privately owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases, using its leading Kinobeads technology. Previously, Tim had various positions at British Biotech plc including Board Director and Acting CEO, and before that was an Investment Banker in London specializing in the healthcare sector. This followed a 14-year period as an entrepreneur in other industrial sectors, managing and developing three privately-held businesses in which he was a major shareholder. Tim Edwards is Chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector; Chairman of The Mulberry Bush Organization, a charity founded in 1948 providing therapeutic and residential care for children aged 5-12 with severe emotional and behavioral difficulties; and a Fellow of the RSA, a charity founded in 1754 which drives ideas, innovation and social change. From 2005-2007, Tim was Chairman of ReOx Limited, a biotech company spun out of the University of Oxford by Peter Ratcliffe FRS and others from the Wellcome Trust Centre for Human Genetics.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Cellzome Inc

Cellzome Inc is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome 's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. Cellzome Inc is a privately-held, international company located in Heidelberg, Germany and Cambridge, UK employing about 100 people.